Immatics (NASDAQ:IMTXW) Short Interest Up 2,257.1% in December

Immatics (NASDAQ:IMTXW) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 16,500 shares, an increase of 2,257.1% from the November 30th total of 700 shares. Based on an average daily volume of 33,600 shares, the days-to-cover ratio is presently 0.5 days.

Immatics Stock Performance

NASDAQ IMTXW traded down $0.01 on Thursday, hitting $0.18. 1,832 shares of the company’s stock traded hands, compared to its average volume of 15,750. The firm’s 50-day moving average price is $0.64 and its two-hundred day moving average price is $1.99. Immatics has a 1-year low of $0.18 and a 1-year high of $4.14.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.